ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Benefits and risks of adding oxaliplatin to adjuvant chemotherapy in patients with high-risk stage II colon cancer

Benefits and risks of adding oxaliplatin to adjuvant chemotherapy in patients with high-risk stage II colon cancer
Outcome Results Absolute effect estimates Quality of evidence Plain language summary
FU + LV FOLFOX
Grade 3 peripheral sensory neuropathy RR: 69.0 (95% CI, 17.0 to 278.0)
(2219 patients in one study during treatment)		 2 per 1000 138 per 1000 Moderate* FOLFOX worsens grade 3 peripheral sensory neuropathy during treatment
Difference: 136 more per 1000 (95% CI, 32 more to 554 more)
OS HR: 0.91 (95% CI, 0.61 to 1.36)
(569 patients in one study)
Follow-up median: 80 months		 167 per 1000 153 per 1000 Low FOLFOX may have little or no effect on OS in patients at high risk of recurrence
Difference: 14 fewer per 1000 (95% CI, 62 fewer to 53 more)
DFS HR: 0.72 (95% CI, 0.51 to 1.01)
(569 patients in one study)
Follow-up median: 63 months		 254 per 1000 190 per 1000 Low FOLFOX may have little or no effect on DFS in patients at high risk of recurrence
Difference: 64 fewer per 1000 (95% CI, 115 fewer to 2 more)
TTR HR: 0.62 (95% CI, 0.41 to 0.92)
(569 patients in one study)
Follow-up median: 63 months		 212 per 1000 137 per 1000 Low FOLFOX may improve TTR in patients at high risk of recurrence
Difference: 75 fewer per 1000 (95% CI, 119 fewer to 13 fewer)
FU: fluorouracil; LV: leucovorin calcium; FOLFOX: fluorouracil, leucovorin, and oxaliplatin; RR: relative risk; OS: overall survival; HR: hazard ratio; DFS: disease-free survival; TTR: time to recurrence; PSN: peripheral sensory neuropathy.
* Downgrade for wide CI. Grade 3 PSN during treatment was reported in 138 patients (12.5%) in the FOLFOX4 group and 0.2% of the patients in the LV 1 FU group. At 18 and 48 months, 0.7% of FOLFOX-treated patients experienced Grade 3 PSN.
¶ Indirectness: population includes stage III patients (MOSAIC trial, 2009). MOSAIC analyses conducted in high-risk subpopulation are considered exploratory.
From: Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol 2021. DOI: 10.1200/JCO.21.02538. Copyright © 2021 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.
Graphic 134891 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟